Response of malignant thymoma to erlotinib.
Christodoulou
C
C
Oncology Department, Metropolitan Hospital, Athens; Alfa Institute of Biomedical Sciences, Athens. Electronic address: c_christodoulou@yahoo.gr.
Murray
S
S
Oncology Department, Metropolitan Hospital, Athens.
Dahabreh
J
J
Athens Medical Center, Athens, Greece.
Petraki
K
K
Oncology Department, Metropolitan Hospital, Athens.
Nikolakopoulou
A
A
Oncology Department, Metropolitan Hospital, Athens.
Mavri
A
A
Alfa Institute of Biomedical Sciences, Athens; Athens Medical Center, Athens, Greece.
Skarlos
D
D
Oncology Department, Metropolitan Hospital, Athens.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D004815:Epidermal Growth Factor / Q000235:genetics / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D000077156:Gefitinib; D006801:Humans; D007150:Immunohistochemistry; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D013945:Thymoma / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D004815:Epidermal Growth Factor; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab; D000077156:Gefitinib